

13 November 2024

Oncology Melanoma

Q1. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage) :

- **Cobimetinib** <5
- **Dabrafenib** <5
- **Dabrafenib + Trametinib** <5
- **Dacarbazine** <5
- **Denosumab** <5
- **Encorafenib + Binimetinib** 8
- **Ipilimumab monotherapy** <5
- **Ipilimumab + Nivolumab** 12
- **Nivolumab monotherapy** 11
- **Nivolumab + Relatlimab** 6
- **Pembrolizumab** 54
- **Trametinib** <5
- **Vemurafenib** <5
- **Vemurafenib + Cobimetinib** <5
- **Other active systemic anti-cancer therapy** Tebentafusp MAP - <5
- **Palliative care only** – To retrieve this information would require a manual trawl of individual patient files which would exceed the 18 hour limit which is set out in Section 12 of the FOI Act (2000).

Where numbers are low we have indicated <5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.

Q2. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:

- **Ipilimumab monotherapy**
- **Ipilimumab + Nivolumab**
- **Nivolumab monotherapy**
- **Nivolumab + Relatlimab**
- **Pembrolizumab**
- **Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)**
- **Other active systemic anti-cancer therapy**
- **Palliative care only**

13 November 2024

To retrieve this information would require a manual trawl of individual patient files which would exceed the 18 hour limit which is set out in Section 12 of the FOI Act (2000).

The application of Section 12 has been applied as it is the extraction of the information which will incur a disproportionate cost. The information you have requested is not centrally held and would require considerable interrogation of the data in order to extract the information request. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

Section 12 of the Freedom of Information Act makes provision for public authorities to refuse requests for information where the cost of dealing with them would exceed the appropriate limit.

Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for melanoma?

- **Ipilimumab (monotherapy) <5**
- **Nivolumab (monotherapy) <5**
- **Nivolumab AND Ipilimumab (combination) 7**
- **Nivolumab AND Relatlimab <5**
- **Pembrolizumab 15**
- **Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib <5**

/Encorafenib AND Binimetinib <5

/Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)

- **Other active systemic anti-cancer therapy <5**

***Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.**

Where numbers are low we have indicated <5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.